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Abstract
Background: Pertussis is a reported vaccine-preventable respiratory disease in China. Because the routine
laboratory methods for diagnosis are not in use, the reported cases are mainly in infants with classical paroxysmal
cough and the true incidence related to pertussis is most likely under estimated. In China, however, few studies
have attempted to address this issue. The purpose of this cross sectional study was to estimate the incidence rates
using the method of sero-epidemiology of immunoglobulin (Ig) G antibodies against pertussis toxin (PT) among
healthy populations in China.
Methods: Blood samples were obtained from 1313 healthy individuals aged 0 to 95 years in Guangdong province
of China throughout September 2010. Serum IgG antibodies against PT were determined by commercial ELISA kits.
Subjects with concentration of anti-PT IgG higher than 30 IU/mL were indicated to have recent Bordetella pertussis
infection, if they have not received a booster dose of pertussis vaccine within one year.
Results: Of the 1313 study subjects, 117 (8.91%) were found to have anti-PT antibodies higher than 30 IU/mL.
The estimated incidence of recent infection was thus 9395 per 100,000 for individuals older than 7 years. Peaks of
the estimated incidence rate of recent infection were found to be 11561 per 100,000 in age group of 41–50 years
and 11428 per 100,000 in the group aged 13–19 years.
Conclusions: Our study indicated that B.pertussis infections are considerablely common, particularly in adolescents
and adults in China. The study also stresses the importance of laboratory diagnosis for pertussis and employment
of booster dose of pertussis vaccine in adolescents and adults in this country.
Keywords: Pertussis, Cross-sectional study, Sero-epidemiology, Anti-PT IgG, China
Background
Pertussis, mainly caused by Bordetella pertussis is a very
communicable disease and primarily affects infants and
younger children. Although the disease has been well
controlled worldwide since the routine childhood vac-
cination began in the 1950s, many studies have reported
re-emergence of pertussis in European countries and the
United States since 1990s. Because of increased circu-
lation of B. pertussis and waning vaccine-induced im-
munity among adults and adolescents, they are the
significant source of infection to neonates and younger
infants [1]. Studies suggested that there were approxi-
mately 48.5 million annual cases of pertussis worldwide,
with 295,000 deaths [2,3].
In China, use of whole cell pertussis vaccine combined
with diphtheria and tetanus toxoids (DTwP) was started
in 1980s. Since 2007, a combined diphtheria-tetanus-
acelluar pertussis vaccine (DTaP) has been introduced.
Both DTwP and DTaP vaccines are now in use and
administered in the 3th, 4th and 5th months of life. A
booster dose with DTwP or DTaP is given to children
aged 18–24 months. According to China official country
estimates, the immunization coverage rates and number
of districts achieved with 3 doses of DTP vaccination in
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childhood have been more than 90% since 2002 [4]. The
immunization coverage of four doses was over 99% in
the year of 2011.
Guangdong province is located in Southern part of
China and is considered one of the most economic
developed regions in this country. There are 21
prefectural-Level cities with total 104.3 million inhabi-
tants. The vaccination program used in the Guangdong
province is the same as the above-mentioned national
program. Since 2010 only DTap vaccine is used for per-
tussis immunizations. The immunization coverage rate
has been more than 95% since 1999 in province.
Pertussis is a reportable infectious disease and the
number of reported cases has been decreasing in China.
Pertussis is clinically diagnosed, and laboratory methods
such as serology of ELISA, PCR and culture are not
routinely used. Since the 1990s, notified incidence has
been less than 1 case per 100,000 population [5,6]. From
2004 to 2011, incidence of pertussis by notification
decreased from 0.36 per 100,000 to 0.18 per 100,000.
The death rate due to pertussis was less than 0.2%.
[7]. Of the 22,571 cases reported during the period of
2004–2011, almost 8,533 (37.8%) were infants. More-
over, a larger proportion of reported cases occurred
among children who migrated from rural areas to urban
areas with their families. In 2009, only 1,616 cases
were reported in China and 17 cases were reported in
Guangdong province [8]. Because adults and adolescents
often have atypical “whooping cough” symptoms and do
not usually seek physicians, the true incidence of pertus-
sis is most likely underestimated[9].
Pertussis toxin (PT) is the most specific antigen for per-
tussis and cross-reacting antigens have not been described
[10]. All of licensed DTaP vaccines contain purified PT.
Therefore, IgG antibodies against PT are either a specific
indicator of recent pertussis infection in general popula-
tion [11] or one of indicators for surveillance of the effect-
iveness of the DTaP vaccines in vaccinated population.
In this study, we wanted to determine concentrations
of IgG antibodies to PT among healthy population in
Guangdong province, in order to gain an insight into
seroepidemiology of pertussis in China, incidence of per-
tussis infection estimated in adolescents and adults and
level of anti-PT IgG antibodies in children (less than
7 years old) vaccinated with DTP vaccines before the life
of two years. This study also assessed trends of pertussis
and implications for prevention strategies independent
of notification and diagnostic bias.
Methods
Subjects and study design
Only healthy individuals were enrolled in the study
in Guangdong province (with a population of 104.3 mil-
lion) throughout September 2010. The sample size
calculated for this present study was based on the previ-
ous results of sero-surveillance of immune response to
DTP vaccine and references related to sero-prevalence
of pertussis conducted in other provinces [12-16] The
calculation of the number of subjects needed in this
study was based on the formula n1 =Z
2(1-P)/ε2P. For age
group of less than 14 years old and over 15 years old, P
represented 35% and 15% of pertussis sero-positivity re-
spectively and relative permissible error (ε) was set at
30%. When the ratio of lost follow-up 10% was taken
into account, 1.5 times cluster sampling ratio and sub-
jects’ home location evenly distributed in cities and
counties, a total of 1138 subjects were needed to be en-
rolled in this study. In terms of sampling method,
all subjects were selected randomly from one county
or administrative district affiliated to each of 21
prefectural-Level cities. All subjects were asymptomatic
while entering the study. Three individuals with sign
of respiratory diseases were excluded. A total of 1323
subjects were recruited. Basic demographic data, for
example, age, gender, history of DTP vaccination,
address and cough symptom lasting more than one week
was recorded at the time of blood sampling. Especially,
regarding to the history of DTP vaccination, the vaccin-
ation coverage rate of sampling cities was recorded in
local Center for Diseases Control and Prevention, and
vaccination information for single child subject less than
7 years old was collected from certificates brought by
parents or guardians.
Laboratory methods
Three to five mL of venous blood was drawn. Serum
was extracted from the blood samples within 1–2 hours
after arrival to local laborotories and stored at −20 °C
until transported to the laboratory of Guangdong Pro-
vincial CDC using the cold chain system. IgG antibodies
against PT were measured quantitatively by a com-
mercial ELISA kit (Virion\serion GmbH, Würzburg,
Germany), according to the manufacturer’s protocol.
In the ELISA kit, the antibody activities were expressed
in International Units/mL(IU/mL) and referred to the
“First International Standard for Pertussis Antiserum
(Human)”, NIBSC code: 06/140, World Health
Organization (WHO). Results of anti-PT IgG were inter-
preted as positive or negative following the instruction
of kit’s manual. Subjects bearing more than 30 IU/mL
of IgG against PT were considered seropositive, below
20 IU/mL as seronegative. Combined with the recom-
mendations of previous studies, IgG anti-PT titers ≥ 100
IU/mL detected in a single serum sample were a diag-
nostic proof of recent or active B.pertussis infection, if
the subject has not received a booster dose of pertussis
vaccine within the previous one year [17,18]. While a
concentration of ≥30 IU/mL was considered to indicate
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a probable recent contact with B.pertussis, if no booster
has been received within the previous one year.
Statistical analysis
Data analysis was performed using SPSS 13.0 software
(SPSS Inc, Chicago, USA). In order to avoid interference
with vaccination induced antibodies, and for estimating
the incidence rate of infection among school students
(primary school and middle school) and adults, subjects
were stratified into nine subgroups according to their
age: 0–2 years, 3–4 years, 5–6 years, 7–12 years, 13–
19 years, 20–30 years, 31–40 years and 41–50 years,
and ≥ 51 years. All subjects were further divided into two
crossed groups: living in cities or living in counties.
Prevalence of seropositivity of anti-PT IgG and esti-
mated incidence rate of recent B.pertussis infection in all
subjects and each group were descriptively calculated.
Quantitative variables were summarized by means with
their 95% Confidence Interval (CI), and qualitative vari-
ables were expressed as percentages. The chi-squared
test and K independent samples test for qualitative vari-
able, and the one-way ANOVA test for quantitative vari-
ables were used for comparisons between subgroups. A
P value < 0.05 was considered significant. The serological
change trends of anti-PT IgG antibodies by 0–6 year
ages were demonstrated by scatter figure.
Ethical considerations
This study was approved by the Institutional Review
Board (IRB) of Chinese Center for Disease Control and
Prevention. Informed consent was received from all sub-
jects before the blood samples were taken.
Results
Study population
Of the 1323 subjects primarily enrolled in the study,
10 were excluded from the analysis due to absence of
the demographic data or poor quality of blood samples.
Therefore, all following analyses were thus based on the
number of 1313 subjects. Of the 1313 subjects, 654 were
male and 659 were female (gender ratio 1.14), while 660
were city livers and 653 were county livers (ratio 1.01).
All subjects were grouped in nine subgroups: 80 subjects
(6.1%) aged 0–2 years, 79 subjects (6.0%) aged 3–4 years,
79 subjects (6.0%) aged 5–6 years, 61 subjects (4.6%) 7–
12 years, 175 subjects (13.3%) 13–19 years, 256 subjects
(19.5%) 20–30 years, 204 subjects (15.5%) 31–40 years,
173 subjects (13.2%) 41–50 years and 206 subjects
(15.7%) ≥51 years (Table 1). The youngest subject was
a three months old boy, and the oldest was a 95 years
old woman.
Concentrations of IgG antibodies against pertussis toxin
The mean concentration of anti-PT IgG antibodies in
1313 study subjects was 14.21 IU/mL (95%CI: 12.29-
16.13) (Table 1). Low levels of anti-PT antibodies were
observed in all age groups. The mean levels of anti-PT
IgG and 95% CI of each age group were listed in Table 1.
The highest mean concentration of anti-PT IgG was
found in 13–19 years group with 18.44 IU/mL (95% CI
11.08-25.81). The lowest level was 9.95 IU/mL in group
of 3–4 years age. No difference in the mean concentra-
tion of anti-PT IgG was found between subjects living in
cities and counties and between the genders (P = 0.76
and 0.37). Although no difference in the mean concen-
tration of anti-PT IgG antibodies was observed among
nine subgroups by using one-way ANOVA test
(P = 0.55), the mean concentration of anti-PT IgG in
subjects aged 13–19 years was significantly higher than
those aged 7–12 years analyzing by two sample T-test
(P = 0.03).
Sero-prevalence of IgG antibodies against pertussis toxin
among populations aged more than 7 years
Of the 1075 subjects older than 7 years of age, 101
(9.39%, 95%CI 7.65%-11.13%) had anti-PT IgG anti-
bodies higher than 30 IU/mL and were thus consi-
dered seropositive for B.pertussis, and 21 (1.95%, 95%CI
1.12%-2.78%) had concentration of anti-PT IgG anti-
bodies higher than 100 IU/mL (Table 1). The subjects
aged 13–19 years had highest sero-positivity rate 3.43%
(95% CI 0.73%-6.13%) in ≥100 IU/mL category, and the
subjects of 41–50 years age had highest sero-positive
rate 11.56% (95% CI 6.80%-16.32%) in ≥ 30 IU/mL. The
number of study subjects included in the age group of
7 to 12 years was relatively low,and the lowest positivity
rate 6.56% was observed (Table 1). When the sero-
positivity rates were compared among age subgroups,
no statistically significant difference was found by using
Kruskal-Wallis Test (P = 0.437). The sero-positivity rate
of all age groups was shown in Table 1.
Sero-prevalence of anti-PT antibodies among children
younger than 7 years of age
The concentrations of anti-PT IgG antibodies of
238 children less than 7 years old were plotted in
Figure 1. Most of children had anti-PT antibodies below
30 IU/mL. Only three children were found to have anti-
PT IgG antibodies higher than 100 IU/mL. However, the
guardians of the three children didn’t claim that their
children suffered cough at the time of blood sampling.
All children studied had received DTaP or DTwP vac-
cines on time according to the vaccination certificates. A
3-month-old infant had just received first dose of DTaP
vaccine and the anti-PT IgG tested was 52.54 IU/mL.
A 4-month-old infant had received 2 doses of DTaP
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vaccine and the concentration of anti-PT IgG antibodies
was only 2.16 IU/mL. Moreover, the serological trends of
anti-PT IgG level among children (over 6 months old)
who received 3 doses DTP were as similar as that of
children (over 2 two years old) who received booster dose
DTP, and the trend was also no distinctive change till
7 years old children.
The estimated incidence rates of B.pertussis infection
Depending on the pertussis vaccination programs, vari-
ous cutoff values for diagnostic anti-PT IgG antibodies
have been proposed for adolescents and adults [18].
However, there are no available cutoff values of anti-PT
IgG as indication as B.pertussis infection used in China.
In this study, we considered the mean level of anti-PT
IgG of all subjects and the instruction of ELISA kit for
results judgment and previous studies on the decay of
anti-PT IgG titer after infection [17,19] and decided
to apply 30 IU/mL in estimating the incidence rate of
B. pertussis infection. Moreover, the concentration of
anti-PT antibodies expressed as IU/ml in our present
study was equivalent to that expressed as U/ml used in
an earlier study carried out in the Netherlands by de
Melker’s study [17]. In the Dutch study, it was found
that after infection, anti-PT IgG titers take on average
58.6 days to drop to a level of 100 IU/mL and 365 days
(one year) to reach a level of 30 IU/mL, respectively.
Based on 9.39% of subjects more than 7 years age fell in
the category of ≥30 IU/mL, an estimated incidence rate
of probable B.pertussis infection in the year before
the serum sampling is 9.39% (365.25 days/365 days ×
9.39%). In Figure 2, the age-specific incidence rates of
infection with B. pertussis in individuals more than
7 years of age are given as calculated for the cut-off
≥30 IU/mL. The age distribution of estimated infec-
tion rates also revealed that the peak of estimated inci-
dence rate of recent infection was in the age catergory
of 41–50 years (11561/100,000), and the second peak of
the estimated recent infection rate was in the group of
Table 1 Demographic data and status of anti-PT IgG antibodies in studied subjects
Subgroup n Mean of anti-PT IgG
and 95% CI (IU/mL)
Pa Number of subjects (%) in concentrations of anti-PT IgG Pc
<30IU/mL ≥30IU/mL ≥100IU/mL
Total 1313 14.21(12.29-16.13) 1196(91.09%) 93(7.08%) 24(1.83%)
Home location
City 660 14.51(11.43-17.58) 0.76 609(92.27%) 51(7.73%) 13(1.97%) 0.18
County 653 13.92(11.62-16.23) 587(89.89%) 66(10.11%) 11(1.68%)
Gender
Male 654 15.09(12.43-17.73) 0.37 589(90.06%) 65(9.94%) 15(2.29%) 0.14
Female 659 13.35(10.57-16.12) 607(92.11%) 52(7.89%) 9(1.36%)
Age (average age)
0-2(1.94) 80 10.91(7.01-14.82) 0.55 72(90%) 8(10.0%) 1(1.25%) 0.44
3-4(4.2) 79 9.95(5.74-14.17) 75(94.94%) 4(5.06%) 1(1.26%)
5-6(5.8) 79 10.80(4.95-16.65) 75(94.94%) 4(5.06%) 1(1.26%)
7-12(9.4) 61 9.45(6.04-12.86) 0.03b 57(93.44%) 4(6.56%) 0(0)
13-19(17.4) 175 18.44(11.08-25.81) 155(88.57%) 20(11.43%) 6(3.43%)
20-30(23.8) 256 15.70(9.89-21.5) 237(92.58%) 19(7.42%) 6(2.34%)
31-40(35.7) 204 13.60(9.85-17.34) 188(92.16%) 16(7.84%) 3(1.47%)
41-50(46.0) 173 15.42(9.34-21.51) 153(88.44%) 20(11.56%) 3(1.73%)
> 51(64.5) 206 14.02(10.94-17.10) 184(89.32%) 22(10.68%) 3(1.46%)
a Based on two sample t-test and one-Way ANOVA.
b Two sample t-test between 1–2 years and 13–19 years group.
c Based on nonparametric tests for 2 independent sample and Kruskal-wallis H.
Figure 1 Concentrations of anti-PT IgG antibodies in 238
healthy children aged less than 7 years. Each symbol represents
one subject. Solid line presents mean level of IgG using local
regression analysis.
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13–19 years age (11428/100,000). The estimated inci-
dence rate of the adolescence and adults produced ten
thousand times higher than that reported in China.
Discussion
In China, 90% reported pertussis cases were infants or
young children who suffered from classical “whooping
cough” symptoms. Studies suggested that only 40-50% of
pertussis cases had a classical clinical manifestation of a
paroxysmal cough [20], often leading to a misdiagnosis
as a general respiratory infection and a failure to investi-
gate for pertussis. Since the methods for laboratory
confirmation of B.pertussis were not routinely used in
China, many of pertussis cases without classical paro-
xysmal cough symptom among vaccinated children,
adolescents and adults failed to be notified and were
possibly considered as common respiratory infections.
The misdiagnoses clearly contributed to the reported
low incidence under the 1 per 100,000 since 1990s in
China. In Guangdong, the number of reported pertussis
cases ranged from 18 to 115 cases in each year during
the period of 2004–2011, and only one death was
reported in 2005. There were only 18 and 22 cases noti-
fied in 2010 and 2009. Therefore this cross sectional
study was aimed to investigate seroprevalence of pertus-
sis in all age groups in a region of China.
Threshold employed in this study were based on com-
bination of mean value of anti-PT IgG of studied
population, China pertussis vaccine programs, instruc-
tion of ELISA kit and previous studies of EU. Mean con-
centration of anti-PT IgG in subgroups of subjects was
relatively low fluctuating between 10 IU/mL and 20 IU/
mL. This result was similar to our recent study carried
out in Shandong province, eastern part of China [21]. In
China, no booster dose was used in adolescents and/or
adults. The levels of anti-PT IgG antibodies observed in
China might be lower than that of European countries
and US in which boosters for adolescents and young
adults were introduced [22,23]. Regarding the perform-
ance of available commercial ELISA kits for diagnosis
of pertussis, a recent German study showed that only
kits using PT as a coating antigen gave overall good
sensitivities and specificities compared to their in-house
ELISA [18], suggesting that our results obtained by
using the commercial ELISA kits are true. Therefore,
considering the high specificity of anti-PT IgG, one cut-
off was set at 30 IU/mL rather than a higher cut-off with
lower sensitivity, which was used to indicate a probable
recent contact with B.pertussis, if no booster has been
received within the previous one year. Various cutoff
values for anti-PT IgG with recent contact to B. pertussis
antigens have been proposed by various countries
[19,24-26]. In this study, we also applied the diagnostic
algorithm described by Riffelmann that anti-PT IgG




























Figure 2 The age-sepcific estimated incidence rates of B.pertussis infection per 100,000 in the year before serum sampling based on
the cut-off 30IU/mL.
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In order to avoid the possible influence of antibodies
derived from vaccinations, we mainly estimated the inci-
dence rates among individuals older than 7 years age
based on high anti-PT IgG titer in serum sample. It is
known that the vaccine-induced antibodies began to
wane 3 to 5 years after the last dose of vaccination, and
immunity to pertussis vaccine diminished to 0%-20%
over a 10-year interval [27,28]. Primary pertussis vac-
cination in China has been targeted routinely only at
the infant age group with a fourth dose injected at 18–
24 months, and no further booster doses were used in
this country. High level of anti-PT IgG antibodies in
subjects older than 7 years age are most likely due to
contact of B.pertussis. Therefore, information about the
sero-prevalence of high levels of anti-PT antibodies in
combination with the post-infection antibody decline
rate allows us to study B.pertussis infections in > 7 years
age groups irrespective of clinical manifestation and
reporting symptom.
Our results clearly showed that despite a high vaccin-
ation coverage (>98%) in Guangdong province, pertussis
is common in the communities, particularly in the ado-
lescents and adults. The estimated incidence rate of re-
cent infection was found that 9.39% (or 9395 per
100,000) of the population older than 7 years of age had
experienced contact with B. pertussis in the year before
sampling, which was found to be ten thousand times
higher compared to that based on the notifications in
2010 (0.176/100,000). Many countries have observed
pertussis is under-reported and under-diagnosed [29],
for example, the estimated incidence rates of infection is
more than 600-times higher than the notified cases
numbers in Netherland [17]. We have to realize that
raised anti-PT IgG antibodies could reflect exposure/
infection rather than clinical disease. Due to absence of
clinical symptom, many adults cases with higher anti-PT
IgG were considered as atypical or asymptomatic infec-
tion. The high proportion of study subjects with atypical
or asymptomatic infection clearly contributed to the
high estimated incidence rate of infection observed in
this study. It remains to be shown if the pathogen of
B. pertussis could be transmitted by subjects with
asymptomatic or atypical infections.
Previous studies suggest that the amount of under-
reporting in pertussis varies among different age groups,
and the under reporting was higher for older children,
adolescents, and adults than for younger children
[30,31]. Our results were in consistent with the earlier
findings. In this study, the higher incidences were
observed in adolescents and adults older than 40 years
of age. Due to more crowding students in schools,
high rate of person to person transmission in this age
group can occur and therefore the incidence rate of
recent infection was highest. In addition, our data also
revealed the relative higher sero-positive among pop-
ulation living in county than in city. According to the
reported vaccination coverage rate in Guangdong prov-
ince, the lower access to health facilities didn’t seem
to produce lower immunization coverage. One explan-
ation might be that due to the low number of hospitals
or department of diseases control and prevention and
lack of awareness to pertussis, subjects with pertussis
could not be diagnosed or could not have access to
treatment and control strategy. This may have resulted
in disease transmission.
The concentrations of anti-PT antibodies induced by
vaccination or by infection couldn’t be differentiated
by laboratory technique, eg, ELISA, but in this study, a
distinctively increased level of anti-PT IgG was not
noted after fresh vaccination among 0–2 years group.
In China, children receive four doses of pertussis vac-
cines before two years of age. Therefore, higher level of
anti-PT antibodies in age group 0–2 compared to other
age groups would have been expected. In this present
study, however, we did not observe such a difference.
One explanation might be that homemade DTwP or
DTaP vaccines from various manufactuers differ con-
siderably in their immunogenicity. According to the
Chinese Pharmacopoeia, DTaP are mainly composed of
PT and FHA in pertussis ingrendients, but the propor-
tion and content of two antigens were not described in
instruction. It was indicated in other study that apart
from high anti-PT antibody titers as correlate of pro-
tection, high titer of anti-FHA Antibody can also pro-
vide some protection against pertussis [32]. This could
be one explanation. In this study we didn’t measure
anti-FHA Abs among children who received home-
made DTP vaccines. However we believed that the in-
creasing immunization coverage in China should
contribute to the decreasing trend in pertussis cases
reported. Unfortunately we do not have efficacy data
from the vaccine trials in China. Another explanation
might be the low number of studied subjects included
in the age group.
We had to realize that the serological cut-off value
for estimating the incidence was consulted to the
data of present study on asymptomatic population
and previous studies of EU. We have not validated
its power for diagnosing pertussis patients who were
confirmed by other methods such as PCR or culture.
A prospective cohort study on pertussis infection in
hospitalization is being planned in China CDC in
which all three laboratory methods PCR, culture and
serology ELISA will be used. Since China is a big coun-
try with 1.3 billion populations and this study was only
carried out in one province, a multi-center studies should
be conducted to further understand the burden of pertus-
sis in this country.
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Conclusion
In conclusion, our study indicated that in China
B.pertussis infections are considerablely common, par-
ticularly in adolescents and adults. This study also stres-
ses the importance of laboratory diagnosis for pertussis
and employment of booster dose of pertussis vaccine in
adolescents and adults in China.
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